Bafisontamab clinical trials
Also written EMB-01 and FIT-013a.
How each study uses bafisontamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bafisontamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Shanghai EpimAb Biotherapeutics Co., Ltd. (4) · Rose Research Center, LLC (1)
Studies
Open first, then newest update. How each study uses bafisontamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer PatientsRecruitingPhase 2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT07314294Written as EMB-01 1600 mg administered once weekly throughout the study
- EMB-01 in Patients With Advanced/Metastatic Gastrointestinal CancersRecruitingPhase 1/2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT05176665Written as EMB-01
- EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung CancerNot yet recruitingPhase 1/2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT05498389Written as EMB-01
- A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid TumorsRecruitingPhase 1/2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT03797391Written as EMB-01
- Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation TreatmentStatus unknownPhase 2/3Rose Research Center, LLCNCT04868253Written as EMB-01
Given beside what is tested · 1 — bafisontamab is usual care or a partner of the new treatment
Codes
What other systems call bafisontamab · ClinicalTrials.gg INT016643
- UNII (FDA) G86X5QQ7M5BAFISONTAMABOne source FDA
- NCI Thesaurus C158085BafisontamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | G86X5QQ7M5 | BAFISONTAMAB | One source FDA |
| NCI Thesaurus | C158085 | Bafisontamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.